Eversept Partners, LP Syndax Pharmaceuticals Inc Transaction History

Eversept Partners, LP

$993 Million
Q2 2025

A detailed history of Eversept Partners, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Eversept Partners, LP holds 4,065,355 shares of SNDX stock, worth $64.8 Million. This represents 3.84% of its overall portfolio holdings.

Number of Shares

4,065,355

Previous 4,212,270 3.49%

Holding current value

$64.8 Million

Previous $51.8 Million 26.42%

% of portfolio

3.84%

Previous 5.73%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$8.9 - $14.15 $1.31 Million - $2.08 Million	-146,915 Reduced 3.49%	4,065,355 $38.1 Million
Q1 2025 May 15, 2025	BUY	$12.29 - $16.38 $47.5 Million - $63.4 Million	3,868,870 Added 1126.64%	4,212,270 $51.8 Million
Q4 2024 Feb 14, 2025	SELL	$12.52 - $21.81 $47.1 Million - $82 Million	-3,761,913 Reduced 91.64%	343,400 $4.54 Million
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $8.82 Million - $12.2 Million	491,682 Added 13.61%	4,105,313 $79 Million
Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $9.04 Million - $11.4 Million	480,518 Added 15.34%	3,613,631 $74.2 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $4.93 Million - $6.15 Million	-250,131 Reduced 7.39%	3,133,113 $74.6 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $8.96 Million - $17.1 Million	786,999 Added 30.31%	3,383,244 $73.1 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $5.9 Million - $8.85 Million	406,513 Added 18.56%	2,596,245 $37.7 Million
Q2 2023 Nov 08, 2023	SELL	$19.35 - $22.31 $373,938 - $431,140	-19,325 Reduced 0.87%	2,189,732 $45.8 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $373,938 - $431,140	-19,325 Reduced 0.87%	2,189,732 $45.8 Million
Q1 2023 Nov 08, 2023	BUY	$20.66 - $28.98 $12.2 Million - $17.1 Million	588,344 Added 36.3%	2,209,057 $46.7 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $12.2 Million - $17.1 Million	588,344 Added 36.3%	2,209,057 $46.7 Million
Q4 2022 Nov 08, 2023	BUY	$20.64 - $26.24 $8.45 Million - $10.7 Million	409,279 Added 33.78%	1,620,713 $41.2 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $8.45 Million - $10.7 Million	409,279 Added 33.78%	1,620,713 $41.2 Million
Q3 2022 Nov 08, 2023	BUY	$18.51 - $24.79 $4.02 Million - $5.38 Million	217,072 Added 21.83%	1,211,434 $29.1 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $4.02 Million - $5.38 Million	217,072 Added 21.83%	1,211,434 $29.1 Million
Q2 2022 Nov 08, 2023	SELL	$13.64 - $19.48 $16.3 Million - $23.3 Million	-1,195,370 Reduced 54.59%	994,362 $19.1 Million
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $13.6 Million - $19.4 Million	994,362 New	994,362 $19.1 Million

Others Institutions Holding SNDX

# of Institutions

248

Shares Held

100M

Call Options Held

1.28M

Put Options Held

1.29M

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $901M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account

Eversept Partners, LP Syndax Pharmaceuticals Inc Transaction History